Mai Nguyen Thi, Lan Ngo Thi, Vu Thien Y, Duong Phuong Thi Mai, Tung Nguyen Thanh, Phung Huong Thi Thu
Laboratory of Theoretical and Computational Biophysics, Ho Chi Minh City, Viet Nam; Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City, Viet Nam.
Institute of Materials Science & Graduate University of Science and Technology, Academy of Science and Technology, Hanoi, Viet Nam.
J Mol Graph Model. 2020 Nov;100:107648. doi: 10.1016/j.jmgm.2020.107648. Epub 2020 Jun 26.
Checkpoint kinase 1 (CHK1) is a serine/threonine-protein kinase that is involved in cell cycle regulation in eukaryotes. Inhibition of CHK1 is thus considered as a promising approach in cancer therapy. In this study, the fast pulling of ligand (FPL) process was applied to predict the relative binding affinities of CHK1 inhibitors using non-equilibrium molecular dynamics (MD) simulations. The work of external harmonic forces to pull the ligand out of the binding cavity strongly correlated with the experimental binding affinity of CHK1 inhibitors with the correlation coefficient of R = -0.88 and an overall root mean square error (RMSE) of 0.99 kcal/mol. The data indicate that the FPL method is highly accurate in predicting the relative binding free energies of CHK1 inhibitors with an affordable CPU time. A new set of molecules were designed based on the molecular modeling of interactions between the known inhibitor and CHK1 as inhibitory candidates. Molecular docking and FPL results exhibited that the binding affinities of developed ligands were similar to the known inhibitor in interaction with the catalytic site of CHK1, producing very potential CHK1 inhibitors of that the inhibitory activities should be further evaluated in vitro.
检验点激酶1(CHK1)是一种丝氨酸/苏氨酸蛋白激酶,参与真核生物的细胞周期调控。因此,抑制CHK1被认为是癌症治疗中的一种有前景的方法。在本研究中,采用配体快速拉动(FPL)过程,利用非平衡分子动力学(MD)模拟预测CHK1抑制剂的相对结合亲和力。将配体从结合腔中拉出的外部简谐力的功与CHK1抑制剂的实验结合亲和力高度相关,相关系数R = -0.88,总体均方根误差(RMSE)为0.99 kcal/mol。数据表明,FPL方法在预测CHK1抑制剂的相对结合自由能方面具有很高的准确性,且所需的CPU时间合理。基于已知抑制剂与CHK1之间相互作用的分子模型,设计了一组新的分子作为抑制候选物。分子对接和FPL结果表明,所开发配体与CHK1催化位点相互作用时的结合亲和力与已知抑制剂相似,产生了非常有潜力的CHK1抑制剂,其抑制活性应进一步在体外进行评估。